Literature DB >> 6310051

Novel drug of choice in Eaton-Lambert syndrome.

H Lundh, O Nilsson, I Rosén.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1983        PMID： 6310051      PMCID： PMC1027495          DOI： 10.1136/jnnp.46.7.684

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN： 0022-3050            Impact factor:   10.154


× No keyword cloud information.
  4 in total

1.  Electromyography and electric stimulation of nerves in diseases of motor unit; observations on myasthenic syndrome associated with malignant tumors.

Authors:  L M EATON; E H LAMBERT
Journal:  J Am Med Assoc       Date:  1957-03-30

2.  Detailed analysis of neuromuscular transmission in a patient with the myasthenic syndrome sometimes associated with bronchogenic carcinoma.

Authors:  D Elmqvist; E H Lambert
Journal:  Mayo Clin Proc       Date:  1968-10       Impact factor: 7.616

3.  [Comparison of acute toxicity of some aminopyridines in vivo (mice) and in vitro (tissue culture)].

Authors:  P Lechat; G Deysson; M Lemeignan; M Adolphe
Journal:  Ann Pharm Fr       Date:  1968-05

4.  Potency of 3,4-diaminopyridine and 4-aminopyridine on mammalian neuromuscular transmission and the effect of pH changes.

Authors:  J Molgó; H Lundh; S Thesleff
Journal:  Eur J Pharmacol       Date:  1980-01-11       Impact factor: 4.432
  4 in total
  7 in total

Review 1.  Treatment for Lambert-Eaton myasthenic syndrome.

Authors:  Michael Keogh; Saam Sedehizadeh; Paul Maddison
Journal:  Cochrane Database Syst Rev       Date:  2011-02-16

2.  Cancer-associated myasthenic (Eaton-Lambert) syndrome: distribution of abnormality and effect of treatment.

Authors:  D A Ingram; G R Davis; M S Schwartz; M Traub; A C Newland; M Swash
Journal:  J Neurol Neurosurg Psychiatry       Date:  1984-08       Impact factor: 10.154

3.  Improvement in neuromuscular transmission in myasthenia gravis by 3,4-diaminopyridine.

Authors:  H Lundh; O Nilsson; I Rosén
Journal:  Eur Arch Psychiatry Neurol Sci       Date:  1985

Review 4.  3,4-Diaminopyridine, an orphan drug, in the symptomatic treatment of Lambert-Eaton myasthenic syndrome.

Authors:  J Molgó; J M Guglielmi
Journal:  Pflugers Arch       Date:  1996       Impact factor: 3.657

5.  Update on treatment options for Lambert-Eaton myasthenic syndrome: focus on use of amifampridine.

Authors:  Sabine Lindquist; Martin Stangel
Journal:  Neuropsychiatr Dis Treat       Date:  2011-05-30       Impact factor: 2.570

6.  3,4-diaminopyridine base effectively treats the weakness of Lambert-Eaton myasthenia.

Authors:  Donald B Sanders; Vern C Juel; Yadollah Harati; A Gordon Smith; Amanda C Peltier; Tessa Marburger; Jau-Shin Lou; Robert M Pascuzzi; David P Richman; Tai Xie; Valentin Demmel; Laura R Jacobus; Kathy L Aleš; David P Jacobus
Journal:  Muscle Nerve       Date:  2018-02-02       Impact factor: 3.217

7.  Population Pharmacokinetics/Pharmacodynamics of 3,4-Diaminopyridine Free Base in Patients With Lambert-Eaton Myasthenia.

Authors:  Nilay Thakkar; Jeffrey T Guptill; Kathy Aleš; David Jacobus; Laura Jacobus; Charles Peloquin; Michael Cohen-Wolkowiez; Daniel Gonzalez
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2017-07-24
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.